Vor Biopharma Inc. (NYSE:VOR) Given Average Rating of “Buy” by Analysts

Shares of Vor Biopharma Inc. (NYSE:VOR) have earned a consensus recommendation of “Buy” from the seven analysts that are covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $11.36.

A number of equities analysts have issued reports on the company. Robert W. Baird cut their price target on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. JMP Securities restated a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a report on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Finally, Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Vor Biopharma in a research report on Monday, December 9th.

Institutional Trading of Vor Biopharma

A number of institutional investors have recently added to or reduced their stakes in the stock. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Vor Biopharma in the 4th quarter valued at $33,000. Rosalind Advisors Inc. purchased a new stake in shares of Vor Biopharma in the third quarter worth $54,000. Virtu Financial LLC bought a new stake in Vor Biopharma during the fourth quarter valued at $60,000. XTX Topco Ltd purchased a new position in Vor Biopharma during the fourth quarter worth about $80,000. Finally, Trustees of Columbia University in the City of New York bought a new position in Vor Biopharma in the 4th quarter worth about $102,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Price Performance

Shares of Vor Biopharma stock opened at $0.99 on Friday. The stock’s 50-day moving average is $1.33 and its 200 day moving average is $1.01. Vor Biopharma has a one year low of $0.63 and a one year high of $2.43. The firm has a market cap of $67.64 million, a price-to-earnings ratio of -0.60 and a beta of -0.40.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.